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coma was estimated at €627/year. Independent cost drivers were
IOP (p < 0.001), MD (p < 0.001), ÄMD (p = 0.03) and PEX
(p < 0.001). Prevalence of PEX was associated with 21% higher
costs. Each one-unit increase in mmHg (IOP), decrease in dB
(MD) or ÄdB/year (ÄMD) increased costs by 2.9 %, 1.2% and
5.7%, respectively. Patients that had visited a low-vision centre at
least once had 46% higher annual costs than the average patient.
CONCLUSION: MD, ÄMD, IOP, and PEX are all drivers of
medical cost of glaucoma in Sweden. Further, the variables are
predicting cost independently of each other.
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ANTI-TNF ALPHATHERAPY IN PLAQUE PSORIASIS
Lloyd AC1,Webber JM2, Lebmeier M3, Conway P4,Warburton J3
1Fourth Hurdle Consulting, London, UK, 2Fourth Hurdle Consulting
Ltd, London, UK, 3Wyeth Pharmaceuticals, Maidenhead, UK, 4Wyeth
Europa, Berkshire, UK
OBJECTIVE: To assess the cost-effectiveness of intermittent vs.
continuous anti-TNF alpha therapies in chronic plaque psoriasis.
METHODS: An economic model was constructed to estimate
the cost per month in remission for intermittent etanercept 25 mg
twice weekly (biw) or 50 mg biw, continuous adalimumab or
continuous inﬂiximab compared with no systemic therapy
(NST). Patients considered had chronic plaque psoriasis with
both Psoriasis Area and Severity Index (PASI) and Dermatology
Life Quality Index (DLQI) > = 10 at baseline, and so would be
eligible for anti-TNF alpha treatment under UK guidelines.
Remission was deﬁned at patients experiencing an improvement
of at least 75% of their baseline PASI. Response rates were taken
from registration studies for each agent: maintenance of response
with continuous therapy and likelihood of response to intermit-
tent therapy were extrapolated from published studies to a time
horizon of ten years using a Markov process. Costs were
estimated from a UK payer perspective including drug cost,
administration visits and hospital stay for treatment failures.
RESULTS: Cost per month in remission for each therapy com-
pared with NST was estimated to be: GBP162 (95% CI: 93–287)
for etanercept 25 mg biw; GBP418 (337–531) for etanercept
50 mg biw; GBP1,867 (1,643–2,136) for inﬂiximab and GBP588
(452–804) for adalimumab. The cost-effectiveness ratios
for continuous therapies were sensitive to the criteria used for
withdrawal from treatment. The cost-effectiveness ratios for
intermittent therapy were sensitive to the duration of treatment
interruption achieved and response rate after therapy re-
introduction. All regimens were found to be particularly ap-
propriate in psoriasis patients with severe disease at baseline.
CONCLUSION: The model found intermittent treatment with
etanercept to be more efﬁcient than continuous treatment with
other anti-TNF alpha therapies, as it allows patients to be main-
tained in response at lower drug cost.
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OBJECTIVE: To evaluate the cost-effectiveness of ranibizumab
versus photodynamic therapy with verteporﬁn (PDT-V) and best
standard care (BSC) for the treatment of all wet age-related
macular degeneration (AMD) lesion subtypes (predominantly
classic (PC), minimally classic (MC) and occult lesions (OC)) in
Canada. METHODS: A ten-year Markov model with three-
month cycles was adapted to the Canadian setting to simulate the
evolution of visual acuity (VA) levels in subfoveal wet AMD
patients according to Canadian guidelines. Analyses were per-
formed from the perspective of the Ontario Ministry of Health
with each AMD subtype modeled separately. The initial distri-
bution of patients across VA levels followed the distribution
observed in MARINA and ANCHOR (sham controlled phase III
randomized multicentre clinical trials) at randomization. Transi-
tion probabilities were based on data from the same trials.
Treatment with 0.5 mg ranibizumab was assumed, with nine
injections in year 1 and six injections in year 2. Treatment dura-
tion was assumed to be one year for PC and two years for MC
and OC lesions. Five clinicians completed a resource use ques-
tionnaire from which therapy and adverse event costs were esti-
mated (2007 CDN$). Quality-of-life estimates were obtained
from a time trade-off study carried out in a sample of the UK
general population. Outcomes were measured in terms of
quality-adjusted-life-years (QALY) and discounted (along with
costs) at 5% annually. One-way and probabilistic sensitivity
analyses were performed to estimate uncertainty around incre-
mental cost-effectiveness ratios (ICER). RESULTS: Ranibizumab
demonstrated cost-effectiveness relative to PDT-V and BSC in all
lesion types assuming a $50,000 threshold. The ICER for PC
lesions was $4,167/QALY and $21,857/QALY relative to PDT-V
and BSC respectively. For MC and OC lesions the ICER was
$37,363/QALY and $38,151/QALY respectively relative to BSC.
CONCLUSION: Ranibizumab offers good value for money
compared to current standard treatments for all wet AMD lesion
types.
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OBJECTIVE: To compare cost-effectiveness of topical prostag-
landins for maintaining persistency during the ﬁrst 2 years after
initiating therapy. METHODS: Data derived from Ingenix
managed care database. Patients with latanoprost (LAT), bimato-
prost (BIM), travoprost (TRAV) dispensed between Janaury 1,
2004–December 31, 2004 screened for inclusion. Index
agent = ﬁrst agent ﬁlled; index date = ﬁll date. Patients excluded
if: < 40 years old; not continuously enrolled for 180 days before
index date; had any ocular hypotensive dispensed or no glau-
coma diagnosis within 180 days before index date. Data cen-
sored at the earliest of end of enrollment; end of study (December
31, 2005); or upon adding/switching to a new agent. Cox regres-
sion (adjusted for age, gender, recent diagnosis of preglaucoma/
ocular hypertension) used to compare relative risk of discon-
tinuation of initial prostaglandin and produce survival (on
therapy) plot over ﬁrst 720 treatment days for each prostaglan-
din. Area under survival curve used to estimate expected days on
therapy. RESULTS: A total of 9124 patients met inclusion crite-
ria (LAT, n = 5816; BIM, n = 1665; TRAV, n = 1643). Relative
risk of discontinuing index prostaglandin over ﬁrst 2 years was
8.3% higher for BIM (p = 0.016) and 24.4% higher for TRAV
(p < 0.001). Within the ﬁrst 720 days, expected days of uninter-
rupted, continuous therapy were estimated as 245 for LAT, 226
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for BIM, and 203 for TRAV. The mean drug cost (AWP) was
estimated from actual claims as LAT, $301 (95% CI: $293-
$309); BIM: $364 (95% CI: $344-$384); TRAV: $278 (95% CI:
$263-$294). Compared to TRAV, incremental cost effectiveness
ratio of LAT was $0.56 and of BIM was $3.91 per additional
day of uninterrupted therapy. CONCLUSION: Patients do not
remain on ocular prostaglandins longer than six to seven months
before therapy interruption/discontinuation. Patients using LAT
stayed on therapy longer than those using BIM or TRAV and at
a lower cost per additional day of therapy than BIM.
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OBJECTIVE: In comparison to traditional treatment options,
TNF-á inhibitors have shown promise in increasing the clearance
of psoriatic lesions and improving the quality-of-life of patients
with moderate-to-severe psoriasis. They are however associated
with higher costs and side-effects. The study objective was to
compare the cost-effectiveness of TNF-á inhibitors to other pso-
riasis treatment strategies. METHODS: The cost-effectiveness of
ten treatment options from three drug classes- TNF- á inhibitors,
systemic therapies and phototherapy- were evaluated using a
decision analysis model constructed using DATA Treeage. The
probabilities of success were obtained from PASI-75 scores from
published clinical trials. The annual drug costs were obtained
from the Drug Topics Red Book and published clinical trials.
Additional costs associated with treatment, which included
annual pharmacy costs and costs for professional and institutional
services, were obtained from published reports. Incremental cost
effectiveness ratios (ICERs) were calculated for additional cost
divided by incremental PASI-75 values, and were estimated rela-
tive to the drug with the lowest cost. Multiple sensitivity analyses
were performed to determine the robustness of the ﬁndings.
RESULTS: Phototherapy was found to be the most cost-effective
treatment option with an ICER of $16,435.89/PASI-75, relative
to systemic therapy. The most cost-effective TNF-á inhibitor
was inﬂiximab, with an ICER of $15,733/PASI-75, relative to
adalimumab. Inﬂiximab had the highest drug acquisition cost
($21,250) among the 10 treatment strategies. While Goekerman
therapy with a PASI-75 score of 100 had the highest clinical
effectiveness among all the treatment strategies examined, the
more effective TNF-á inhibitor was inﬂiximab, with a PASI-75
score of 82.3. Sensitivity analysis indicated that the results were
affected by the model assumptions. CONCLUSION: Thus,
phototherapy was found to be the more cost-effective treatment
option in this analysis. It is expected that the cost of TNF-á
inhibitors will be lower in the future.
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OBJECTIVE: To determine the cost-effectiveness ratio for quar-
terly injections of Ranizumab in the treatment of Wet AMD, in
Brazilian HMOs scenario. METHODS: A cost-effectiveness
analysis from the private payers perspective, with a time horizon
of ﬁve years were conducted. A decision tree with a Markov
chain considering the probabilities of increasing, decreasing or
maintaining visual acuity (VA) through ﬁve health states based
on VA from 20/40 to 20/400, were performed. Study compara-
tors examined were Ranibizumab (RAN), and Pegaptanib
Sodium (PEG). The clinical aspects regarding beneﬁts (Vision
Year Gained) and probabilities of transition data were extract
from a meta-analysis of randomized clinical trials for the alter-
natives. Treatment costs including adverse events were collected
from private payers reimbursement reference list for profes-
sional, procedures and diagnostics fees and the drugs costs were
collected from manufactures price list. Costs and beneﬁts were
validated by a panel of Brazilian specialists through the Delphi
technique. The discounting rate was 3% for costs and beneﬁts,
the results were converted in US Dollars (R$ 1.8/USD 1.00). A
one-way sensitivity analysis was performed. RESULTS: Patients
using Ranibizumab get more beneﬁts (RAN = 2.66 per vision
year gained; PEG = 2.00 per vision year gained), with the lowest
total cost per treatment (RAN = $29,653 USD; PEG = $30,093
USD) and the lowest cost per QALY (RAN = $11,148 USD/
vision year gained; PEG = $15,046.5 USD/per vision year
gained). Incremental analysis showed Ranibizumab to be the
dominant alternative. Net beneﬁts are greater with Ranibizumab
independent of willingness to pay. The sensitivity analysis on
efﬁciency and costs of Ranibizumab results show that the results
are sensitive to the type of lesion treated. CONCLUSION:
Ranibizumab is the dominant therapy; it offers better beneﬁts in
vision years gained at the lowest cost. The results are sensitive to
the type of lesion treated, showing the need of guidelines to
assure the best resource allocation.
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OBJECTIVE: To determine the incremental cost-effectiveness of
brimonidine/timolol versus dorzolamide/timolol for lowering
intraocular pressure (IOP). METHODS: A cost-effectiveness
analysis was performed using clinical data from 2 investigator-
masked, randomized, 3-month, parallel-comparison studies
performed at 10 sites. In a post-hoc analysis of those patients
receiving monotherapy treatment for IOP lowering (either
brimonidine/timolol or dorzolamide/timolol) for three months,
the proportion of patients at various IOP levels were calculated
and statistically compared. A three month supply of each drug
was calculated based on their respective WAC price and bottle
size (5 ML brimonidine/timolol and 10 ML dorzolamide/
timolol). The incremental cost-effectiveness ratio (ICER) was
calculated as the difference in drug cost divided by the difference
in the percentage of patients meeting the IOP threshold at three
months between brimonidine/timolol and dorzolamide/timolol.
RESULTS: A 3-month supply of brimonidine/timolol and
dorzolamide/timolol were $169.83 and $154.40, respectively
yielding a cost difference of $15.44. The proportion of patients at
lower IOP thresholds was consistantly higher with brimonidine/
timolol compared to dorzolamide/timolol resulting in a statisti-
cally signiﬁcant incremental beneﬁt for the thresholds from less
than 17mmHg to less than 12mmHg. The associated ICER s for
those thresholds range from $55.12–$85.75 per the percentage
of patients reaching the IOP threshold. CONCLUSION: We
calculated brimondine/timolol to be more cost-effective than
dorzolamide/timolol. Given the importance of achieving target
IOP, both cost and effectiveness should be considered when
evaluating combination therapies for glaucoma.
Abstracts A287
